Poultry
xClose

Loading ...
Swine
xClose

Loading ...
Dairy & Ruminant
xClose

Loading ...
Aquaculture
xClose

Loading ...
Feed
xClose

Loading ...
Animal Health
xClose

Loading ...
Animal Health
Wednesday, October 03, 2012 6:25:44 PM
Print this articleForward this article


Prevalence of Coxiella burnetii in clinically healthy German sheep flocks

      
Angela Hilbert, Gernot Schmoock, Hannah Lenzko, Udo Moog, Roland Diller, Andreas Fröhlich, Lothar Hoffmann, Steffen Horner, Michael Elschner, Herbert Tomaso, Klaus Henning, Heinrich Neubauer and Lisa D Sprague
   
  
Background


Current epidemiological data on the situation of Coxiella (C.) burnetii infections in sheep are missing, making risk assessment and the implementation of counteractive measures difficult. Using the German state of Thuringia as a model example, the estimated sero-, and antigen prevalence of C. burnetii (10% and 25%, respectively) was assessed at flock level in 39/252 randomly selected clinically healthy sheep flocks with more than 100 ewes and unknown abortion rate.


Results


The CHECKITâ„¢ Q-fever Test Kit identified 11 (28%) antibody positive herds, whereas real-time PCR revealed the presence of C. burnetii DNA in 2 (5%) of the flocks. Multiple-locus variable number of tandem repeats analysis of 9 isolates obtained from one flock revealed identical profiles. All isolates contained the plasmid QpH1.


Conclusions


The results demonstrate that C. burnetii is present in clinically inconspicuous sheep flocks and sporadic flare-ups do occur as the notifications to the German animal disease reporting system show. Although C. burnetii infections are not a primary veterinary concern due to the lack of significant clinical impact on animal health (with the exception of goats), the eminent zoonotic risk for humans should not be underestimated. Therefore, strategies combining the interests of public and veterinary public health should include monitoring of flocks, the identification and culling of shedders as well as the administration of protective vaccines.


 
 
For more of the article, please click here.
 
 
Article made possible through the contribution of Angela Hilbert, Gernot Schmoock, Hannah Lenzko, Udo Moog, Roland Diller, Andreas Fröhlich, Lothar Hoffmann, Steffen Horner, Michael Elschner, Herbert Tomaso, Klaus Henning, Heinrich Neubauer, Lisa D Sprague and BioMed Central.

Share this article on FacebookShare this article on TwitterPrint this articleForward this article
Previous
My eFeedLink last read